The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.

PloS One
Hyoung Jin KimHong-Jin Kim

Abstract

Cell growth conditions and purification methods are important in determining biopharmaceutical activity. However, in studies aimed at manufacturing virus-like particles (VLPs) for the purpose of creating a prophylactic vaccine and antigen for human papillomavirus (HPV), the effects of the presence of a resin-bound ligand during purification have never been investigated. In this study, we compared the structural integrity and immunogenicity of two kinds of VLPs derived from HPV type 16 (HPV16 VLPs): one VLP was purified by heparin chromatography (hHPV16 VLP) and the other by cation-exchange chromatography (cHPV16 VLP). The reactivity of anti-HPV16 neutralizing monoclonal antibodies (H16.V5 and H16.E70) towards hHPV16 VLP were significantly higher than the observed cHPV16 VLP reactivities, implying that hHPV16 VLP possesses a greater number of neutralizing epitopes and has a greater potential to elicit anti-HPV16 neutralizing antibodies. After the application of heparin chromatography, HPV16 VLP has a higher affinity for H16.V5 and H16.E70. This result indicates that heparin chromatography is valuable in selecting functional HPV16 VLPs. In regard to VLP immunogenicity, the anti-HPV16 L1 IgG and neutralizing antibody levels elicit...Continue Reading

References

Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·H L GreenstoneJ T Schiller
Mar 12, 2002·Virology·Daniela Tornese BuonamassaGiuliano Bensi
Dec 4, 2003·Journal of Virology·Hans-Christoph SelinkaMartin Sapp
Dec 25, 2003·Journal of Virology·Christopher B BuckJohn T Schiller
Feb 15, 2005·Journal of Virology·Christopher B BuckJohn T Schiller
Jun 2, 2005·Journal of Pharmaceutical Sciences·Li ShiDavid B Volkin
Aug 9, 2005·Trends in Biotechnology·Leonard K PattendenDaniel I Lipin
Jan 5, 2006·Applied and Environmental Microbiology·Karina Araujo AiresPaulo Lee Ho
May 16, 2006·Human Immunology·Yanzheng Zhang, Peter Stastny
Dec 20, 2007·The Journal of General Virology·Raeda Z RizkMichael Pawlita
Dec 21, 2007·Clinical and Vaccine Immunology : CVI·Jianhua SunSonghua Hu
May 2, 2009·Journal of Dental Research·M J Conway, C Meyers
Jul 31, 2009·Journal of Virology·Christina SchellenbacherReinhard Kirnbauer
Aug 19, 2009·Protein Expression and Purification·Hyoung Jin KimHong-Jin Kim
Oct 27, 2009·Archives of Medical Research·Vicente Madrid-MarinaAlejandro García-Carrancá
Jan 6, 2010·Current Opinion in HIV and AIDS·David C Montefiori, John R Mascola
Mar 20, 2010·Clinical and Vaccine Immunology : CVI·David OpalkaMark T Esser
Jun 4, 2010·Gynecologic Oncology·John T SchillerRhonda C Kines
Aug 4, 2011·Journal of Invertebrate Pathology·Tiago VicentePaula M Alves

❮ Previous
Next ❯

Citations

Sep 22, 2012·Human Vaccines & Immunotherapeutics·Qiang Chen, Huafang Lai
Sep 6, 2018·PloS One·Antonina NaskalskaKrzysztof Pyrc
Dec 17, 2015·Pharmacological Reviews·Barbara MulloyClive P Page

❮ Previous
Next ❯

Methods Mentioned

BETA
size-exclusion
ion-exchange chromatography
ELISAs
ELISA
transmission electron microscopy
dynamic light scattering
flow cytometry
protein assay

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.